Opinion|Videos|November 18, 2026

Blood Pressure and Age-Related Hypogonadism Label Changes

Faculty weigh the new class-wide blood pressure warning and why dropping the age-related limitation treats low testosterone as a syndrome, not aging.

In this video, an expert panel explores the latest blood pressure labeling and the FDA’s reconsideration of who qualifies for testosterone therapy.

The strengthened blood pressure warning is real but modest, while the limitation on age-related hypogonadism never had a sound evidentiary basis. Mohit Khera, MD, MBA, MPH, explains that newer products were required to undergo ambulatory blood pressure monitoring, and that the FDA has now extended the resulting warning across all testosterone products. He outlines plausible mechanisms, including sodium retention and erythrocytosis. He recommends routine blood pressure checks, with counseling no more alarming than for other medications with similar effects. Abraham Morgentaler, MD, FACS, notes that longer randomized trials did not detect the increase, suggesting a possibly transient effect. Amy M. Pearlman, MD, favors home monitoring and dose adjustment in the rare patient affected.

Turning to indications, Morgentaler argues that excluding age-related hypogonadism made little sense, since virtually every condition in adult medicine becomes more common with age. He contends the restriction grew out of a period of alarm and litigation and credits the agency for reconsidering a historically skeptical stance. Khera clarifies that the FDA has asked manufacturers to propose updated labeling, mirroring its recent approach to menopausal hormone therapy.

Morgentaler closes by describing low testosterone as a reduced state of the human condition. He calls it a syndrome whose cumulative burden is lost when trials measure symptoms one at a time. Small gains across energy, mood, sexual function, and motivation, he argues, add up to a meaningful difference in how men experience their lives. Clinicians should monitor blood pressure without letting it become a new deterrent and evaluate symptomatic men on their testosterone status rather than their age.

The next episode, ‘Prostate Cancer, BPH, and Testosterone Scheduling Myths,’ examines why the belief that testosterone fuels prostate cancer persisted for decades, what TRAVERSE showed for urinary symptoms, and the case for descheduling.


Related to this article

Rethinking Testosterone Therapy After the FDA Label Revisions
Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.